AGC Biologics vs Bristol Myers Squibb (CGT Mfg): CDMO Comparison
How does AGC Biologics compare to Bristol Myers Squibb (CGT Mfg) for CAR-T manufacturing?
Side-by-side comparison of AGC Biologics and Bristol Myers Squibb (CGT Mfg) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Bristol Myers Squibb (CGT Mfg) has more FDA inspections on record (6 vs 2) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- AGC Biologics has materially broader EMA GMP coverage (23 active certificates vs 1) — stronger EU footprint.
- Bristol Myers Squibb (CGT Mfg) maintains 1 MHRA / UK GMP certificate; AGC Biologics does not.
- Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (584 vs 2) — a broader sponsor book.
- Composite Signal Score: Bristol Myers Squibb (CGT Mfg) 91/100 vs AGC Biologics 81/100 — a 10-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both AGC Biologics and Bristol Myers Squibb (CGT Mfg) qualify as CAR-T manufacturers; Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both AGC Biologics and Bristol Myers Squibb (CGT Mfg) qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: AGC Biologics vs Bristol Myers Squibb (CGT Mfg)
How does AGC Biologics compare to Bristol Myers Squibb (CGT Mfg) for CAR-T manufacturing?
On CDMO Signal's composite Signal Score, AGC Biologics is 81/100 and Bristol Myers Squibb (CGT Mfg) is 91/100; AGC Biologics has 2 FDA inspections on record vs 6 for Bristol Myers Squibb (CGT Mfg); European coverage is 23 active EMA+MHRA certificates for AGC Biologics vs 2 for Bristol Myers Squibb (CGT Mfg). Both are tracked in the CDMO Signal directory as CAR-T CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, AGC Biologics or Bristol Myers Squibb (CGT Mfg)?
Both AGC Biologics and Bristol Myers Squibb (CGT Mfg) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 2 FDA inspections on record; Bristol Myers Squibb (CGT Mfg) has 6.
How do AGC Biologics and Bristol Myers Squibb (CGT Mfg) compare on European GMP coverage?
AGC Biologics holds 23 active EMA GMP certificates and 0 MHRA / UK certificates. Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — AGC Biologics or Bristol Myers Squibb (CGT Mfg)?
AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; Bristol Myers Squibb (CGT Mfg) is matched to 584. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for CAR-T manufacturing — AGC Biologics or Bristol Myers Squibb (CGT Mfg)?
Both AGC Biologics and Bristol Myers Squibb (CGT Mfg) are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →